VIRBAC Stock Rises +2.07% at Friday's Close
Virbac experienced positive momentum in the third quarter of 2025 with a 7.3% growth, driven particularly by strong momentum among its international clientele. The company has revised its annual outlook upwards based on this performance. Analysts' reactions reflect market interest in this case: Oddo BHF raised its price target from 395 to 409 euros, while Kepler Cheuvreux took a constructive stance in early November. On Friday, the stock advanced at the close, regaining ground.
Friday's Trading Performance
The veterinary laboratory's stock advanced 2.07% on Friday, gaining 7 euros to close at 345 euros compared to 338 euros at Thursday's close. This daily recovery occurred against a backdrop of a less enthusiastic market, with the CAC 40 down 0.18% over the same period, revealing a relatively positive performance for Virbac. However, this rebound was not enough to erase the week's losses: the stock dropped 1.71% over seven days. The outlook improves slightly when expanding the horizon: the stock is up 5.34% over three months, although still down 1% over twelve months. In comparison, the flagship index gained 7.88% in a year, widening the gap to Virbac's detriment. A notable point from Friday's session concerns trading activity: only 0.04% of the capital was traded, reflecting extremely limited liquidity. This trait regularly characterizes transactions on Virbac, limiting the interest of institutional investors and actively managed funds. Technically, the price maintains its position above its two major moving averages: the 50-day at 328.33 euros and the 200-day at 321.33 euros, thus providing theoretical support. The key resistance remains at 363 euros while the near support is at 307.50 euros. The average daily volatility, expressed by the ATR, stands at 4.39 euros.
Third Quarter 2025 Results
The results from the third quarter of 2025 form the foundation of the current confidence in Virbac. The group recorded a growth of 7.8%, a significant acceleration driven by the strength of its international activities. This performance led the management to raise its outlook for the entire fiscal year, signaling an acceleration of business flows expected in the fourth quarter. This constructive trajectory has captured the attention of the analyst community. Oddo BHF, maintaining its outperformance rating, substantially increased its price target from 395 to 409 euros, reflecting a more constructive view on the group's fundamentals. Kepler Cheuvreux, for its part, took an aggressive stance at the very beginning of November, joining the chorus of optimistic voices. These changes reflect an upward revaluation of Virbac's ability to generate organic growth while preserving its margins. However, this analytical appetite has not immediately translated into significant flows: the structural weakness of the stock's liquidity continues to temper the engagement of large capitals. Large trades remain rare, limiting the course's progression on the basis of purely mechanical dynamics related to massive capital inflows.
Technical Indicators Analysis
The Relative Strength Index (RSI) stands at 54, a neutral posture without signals of extremes. The MACD reveals a bearish divergence with a negative histogram at -1.70, signaling a weakening of the bullish momentum despite the day's progress. The Bollinger Bands position the stock between 302.46 euros at the bottom and 379.59 euros at the top, placing the current price at the heart of its normal fluctuation zone.
